Prolonged Thrombocytopenia and Severe Transfusion Reaction after ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with Chronic Myelomonocytic Leukemia.

Transfus Med Hemother

Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany.

Published: October 2024

AI Article Synopsis

  • Major ABO-incompatible hematopoietic stem cell transplantation (allo-HCT) can lead to serious complications, including prolonged thrombocytopenia and increased need for platelet transfusions due to persistent anti-donor isoagglutinins.
  • A 55-year-old male with chronic myelomonocytic leukemia experienced significant transfusion reactions after receiving A Rh(D)-negative platelets following his major incompatible allo-HCT.
  • Modifying his platelet transfusion strategy to include only O Rh(D)-negative donors effectively reduced transfusion needs and eliminated reactions, highlighting the importance of isoagglutinin monitoring.

Article Abstract

Introduction: Major ABO-incompatible allogeneic hematopoietic stem cell transplantation (allo-HCT) is a common practice and represents a challenging transfusion scenario. Prolonged thrombocytopenia with increased platelet transfusion needs is one of its reported adverse effects, and this has been linked to the persistence of recipient anti-donor isoagglutinins.

Case Presentation: A 55-year-old male patient, O Rh(D)-positive, with chronic myelomonocytic leukemia underwent major incompatible allo-HCT from a A Rh(D)-negative donor. He presented with prolonged thrombocytopenia and multiple transfusion reactions after A Rh(D)-negative platelet transfusions. Considering the outcomes of numerous examinations, we tested the anti-A1 titers, finding a significant persistence of anti-donor isoagglutinins. We limited platelet transfusions to blood group O Rh(D)-negative donors, which significantly decreased the requirement for platelet transfusions. In addition, the transfusion reactions ceased.

Conclusion: In case of transfusion reactions against platelet products in major ABO-incompatible allo-HCT patients, isoagglutinin monitoring should be considered and a change in the platelet transfusion protocol may be beneficial in patients presenting high isotiters against recipient's blood type.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452149PMC
http://dx.doi.org/10.1159/000534272DOI Listing

Publication Analysis

Top Keywords

prolonged thrombocytopenia
12
transfusion reactions
12
platelet transfusions
12
abo-incompatible allogeneic
8
allogeneic hematopoietic
8
hematopoietic stem
8
stem cell
8
cell transplantation
8
chronic myelomonocytic
8
myelomonocytic leukemia
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!